Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Biocatalyst product sales	$ 3,280	$ 2,020	$ 7,020	$ 5,097
Biocatalyst research and development	12,064	2,533	15,598	4,729
Revenue sharing arrangement	658	1,465	1,380	2,990
Total revenues	16,002	6,018	23,998	12,816
Costs and operating expenses:
Cost of biocatalyst product sales	2,221	1,250	4,710	2,706
Research and development	5,112	5,170	10,798	10,463
Selling, general and administrative	6,420	5,296	13,222	10,874
Total costs and operating expenses	13,753	11,716	28,730	24,043
Income (loss) from operations	2,249	(5,698)	(4,732)	(11,227)
Interest income	13	4	28	8
Other expenses, net	(49)	(96)	(46)	(121)
Income (loss) before income taxes	2,213	(5,790)	(4,750)	(11,340)
Benefit from income taxes	(26)	(430)	(15)	(418)
Net income (loss)	$ 2,239	$ (5,360)	$ (4,735)	$ (10,922)
Net income (loss) per share, basic (usd per share)	$ 0.06	$ (0.14)	$ (0.12)	$ (0.28)
Net income (loss) per share, diluted (usd per share)	$ 0.05	$ (0.14)	$ (0.12)	$ (0.28)
Weighted average common stock shares used in computing net income (loss) per share, basic (shares)	40,495	39,301	40,283	39,066
Weighted average common stock shares used in computing net income (loss) per share, diluted (shares)	41,568	39,301	40,283	39,066